<p>PetMed Express（纳斯达克代码：PETS - 获取免费报告）预计将在 2026 年 12 月 24 日星期三市场开盘前发布其第二季度财报。分析师预计该公司将在本季度宣布每股收益为 0.04 美元。各方可以查看公司即将发布的 2026 年第二季度财报中的信息，以获取关于定于 2025 年 12 月 23 日星期二东部时间凌晨 12:00 的电话会议的最新细节。</p>
<p>获取 <strong>PetMed Express</strong> 警报：</p>
<ul>
<li>Petco Health &amp; Wellness 是否因每股收益超预期而摆脱困境？</li>
</ul>
<p>PetMed Express（纳斯达克代码：PETS - 获取免费报告）最近在 2023 年 10 月 14 日星期二发布了季度财报。该公司报告本季度每股收益为（0.56 美元），低于分析师一致预期的 0.04 美元，差距为（0.60 美元）。该季度的营业收入为 4647 万美元。PetMed Express 的净利润率为负 2.76%，股本回报率为负 6.76%。分析师平均预计 PetMed Express 在当前财政年度的每股收益为 0 美元，下一财政年度的每股收益也为 0 美元。</p>
<h2>PetMed Express 股票表现</h2>
<p>纳斯达克：PETS 周五开盘价为 3.65 美元。该股票的 50 日移动平均价格为 2.34 美元，200 日移动平均价格为 2.89 美元。该股票的市值为 7800 万美元，市盈率为-12.17，贝塔值为 0.75。PetMed Express 的 1 年最低价为 1.57 美元，1 年最高价为 5.58 美元。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>这里有一只不在困境中的宠物股票</li>
</ul>
<p>PETS 曾是多份研究分析报告的主题。Zacks Research 在 2023 年 9 月 29 日的报告中将 PetMed Express 的评级从 “强烈卖出” 上调至 “持有”。华尔街 Zen 在 2023 年 10 月 18 日的研究报告中将 PetMed Express 的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 2023 年 10 月 8 日的研究报告中重申了对 PetMed Express 的 “卖出（d）” 评级。一位研究分析师对该股票给予了 “持有” 评级，另外两位则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”，共识目标价为 3.20 美元。</p>
<p><strong>查看我们对 PetMed Express 的最新分析</strong></p>
<h2>PetMed Express 的机构交易</h2>
<ul>
<li>这 5 只宠物护理股票中的一只可能成为下一个空头挤压</li>
</ul>
<p>一些大型投资者最近对 PETS 的持仓进行了调整。高盛集团在第一季度将其在 PetMed Express 的持股增加了 59.3%。高盛集团目前拥有 33209 股该公司的股票，价值 139000 美元，此前在上个季度购买了 12360 股。Occudo Quantitative Strategies LP 在第二季度获得了 PetMed Express 的新头寸，价值 51000 美元。Bridgeway Capital Management LLC 在第二季度将其在 PetMed Express 的持股增加了 96.2%。Bridgeway Capital Management LLC 目前拥有 40800 股该公司的股票，价值 135000 美元，此前在此期间购买了 20000 股。Oxford Asset Management LLP 在第二季度购买了 PetMed Express 的新头寸，价值 55000 美元。最后，Dimensional Fund Advisors LP 在第三季度将其在 PetMed Express 的持股增加了 5.4%。Dimensional Fund Advisors LP 目前拥有 481517 股该公司的股票，价值 1209000 美元，此前在上个季度购买了 24624 股。机构投资者和对冲基金持有该公司 73.33% 的股票。</p>
<h2>关于 PetMed Express</h2>
<p>（获取免费报告）</p>
<p>PetMed Express, Inc 及其子公司在美国经营宠物药房。该公司销售处方和非处方宠物药物、健康产品及其他狗、猫和马的用品。它提供非处方药物和用品，如跳蚤和蜱虫控制产品、骨骼和关节护理产品、维生素、零食、营养补充品、卫生产品和家庭宠物用品；以及处方药物，包括心丝虫预防药、跳蚤和蜱虫预防药、关节炎、皮肤炎、甲状腺、糖尿病、止痛药、心脏/血压药物及其他特殊药物，以及仿制药替代品。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 PetMed Express 更好</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>高通的巨型反弹有个隐患——这只股票能否继续上涨？</li>
<li>如何投资蓝筹股</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 PetMed Express 吗？</h2>
<p>在你考虑 PetMed Express 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 PetMed Express 并不在名单上。</p>
<p>虽然 PetMed Express 目前在分析师中被评为 “卖出”，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PETS

<p>PetMed Express（纳斯达克代码：PETS）定于 2026 年 12 月 24 日星期三市场开盘前发布其 2026 年第二季度财报。分析师预计每股收益为 0.04 美元。该公司此前报告 2026 年第一季度每股亏损 0.56 美元。该股票的共识评级为 “卖出”，目标价为 3.20 美元。机构投资者持有该公司 73.33% 的股份。PetMed Express 在美国作为一家宠物药房运营，提供处方和非处方药物及宠物用品</p>

<p>PetMed Express (NASDAQ:PETS - Get Free Report) is projected to release its Q2 2026 results before the market opens on Wednesday, December 24th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties may review the information on the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, December 23, 2025 at 12:00 AM ET.</p>
<div class="lb-trans"><p>PetMed Express（纳斯达克代码：PETS - 获取免费报告）预计将在 2026 年 12 月 24 日星期三市场开盘前发布其第二季度财报。分析师预计该公司将在本季度宣布每股收益为 0.04 美元。各方可以查看公司即将发布的 2026 年第二季度财报中的信息，以获取关于定于 2025 年 12 月 23 日星期二东部时间凌晨 12:00 的电话会议的最新细节。</p>
</div><p>Get <strong>PetMed Express</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PetMed Express</strong> 警报：</p>
</div><ul>
<li>Is Petco Health &amp; Wellness Out of the Doghouse on an EPS beat?</li>
</ul>
<div class="lb-trans"><ul>
<li>Petco Health &amp; Wellness 是否因每股收益超预期而摆脱困境？</li>
</ul>
</div><p>PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings results on Tuesday, October 14th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.60). The business had revenue of $46.47 million during the quarter. PetMed Express had a negative net margin of 2.76% and a negative return on equity of 6.76%. On average, analysts expect PetMed Express to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>PetMed Express（纳斯达克代码：PETS - 获取免费报告）最近在 2023 年 10 月 14 日星期二发布了季度财报。该公司报告本季度每股收益为（0.56 美元），低于分析师一致预期的 0.04 美元，差距为（0.60 美元）。该季度的营业收入为 4647 万美元。PetMed Express 的净利润率为负 2.76%，股本回报率为负 6.76%。分析师平均预计 PetMed Express 在当前财政年度的每股收益为 0 美元，下一财政年度的每股收益也为 0 美元。</p>
</div><h2>PetMed Express Stock Performance</h2>
<div class="lb-trans"><h2>PetMed Express 股票表现</h2>
</div><p>NASDAQ:PETS opened at $3.65 on Friday. The stock has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.89. The stock has a market capitalization of $78.00 million, a price-to-earnings ratio of -12.17 and a beta of 0.75. PetMed Express has a 1 year low of $1.57 and a 1 year high of $5.58.</p>
<div class="lb-trans"><p>纳斯达克：PETS 周五开盘价为 3.65 美元。该股票的 50 日移动平均价格为 2.34 美元，200 日移动平均价格为 2.89 美元。该股票的市值为 7800 万美元，市盈率为-12.17，贝塔值为 0.75。PetMed Express 的 1 年最低价为 1.57 美元，1 年最高价为 5.58 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Here’s The One Pet Stock That’s Not in the Doghouse</li>
</ul>
<div class="lb-trans"><ul>
<li>这里有一只不在困境中的宠物股票</li>
</ul>
</div><p>PETS has been the subject of a number of research analyst reports. Zacks Research upgraded shares of PetMed Express from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, September 29th. Wall Street Zen lowered shares of PetMed Express from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of PetMed Express in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Sell&#34; and a consensus price target of $3.20.</p>
<div class="lb-trans"><p>PETS 曾是多份研究分析报告的主题。Zacks Research 在 2023 年 9 月 29 日的报告中将 PetMed Express 的评级从 “强烈卖出” 上调至 “持有”。华尔街 Zen 在 2023 年 10 月 18 日的研究报告中将 PetMed Express 的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 2023 年 10 月 8 日的研究报告中重申了对 PetMed Express 的 “卖出（d）” 评级。一位研究分析师对该股票给予了 “持有” 评级，另外两位则给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”，共识目标价为 3.20 美元。</p>
</div><p><strong>View Our Latest Analysis on PetMed Express</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PetMed Express 的最新分析</strong></p>
</div><h2>Institutional Trading of PetMed Express</h2>
<div class="lb-trans"><h2>PetMed Express 的机构交易</h2>
</div><ul>
<li>One of these 5 Pet Care Stocks Can Be the Next Short Squeeze</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只宠物护理股票中的一只可能成为下一个空头挤压</li>
</ul>
</div><p>A number of large investors have recently made changes to their positions in PETS. Goldman Sachs Group Inc. lifted its holdings in PetMed Express by 59.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company's stock valued at $139,000 after purchasing an additional 12,360 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in PetMed Express in the 2nd quarter valued at $51,000. Bridgeway Capital Management LLC lifted its stake in shares of PetMed Express by 96.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company's stock worth $135,000 after purchasing an additional 20,000 shares during the period. Oxford Asset Management LLP purchased a new position in shares of PetMed Express during the 2nd quarter worth $55,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of PetMed Express by 5.4% during the third quarter. Dimensional Fund Advisors LP now owns 481,517 shares of the company's stock worth $1,209,000 after purchasing an additional 24,624 shares during the last quarter. Institutional investors and hedge funds own 73.33% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近对 PETS 的持仓进行了调整。高盛集团在第一季度将其在 PetMed Express 的持股增加了 59.3%。高盛集团目前拥有 33209 股该公司的股票，价值 139000 美元，此前在上个季度购买了 12360 股。Occudo Quantitative Strategies LP 在第二季度获得了 PetMed Express 的新头寸，价值 51000 美元。Bridgeway Capital Management LLC 在第二季度将其在 PetMed Express 的持股增加了 96.2%。Bridgeway Capital Management LLC 目前拥有 40800 股该公司的股票，价值 135000 美元，此前在此期间购买了 20000 股。Oxford Asset Management LLP 在第二季度购买了 PetMed Express 的新头寸，价值 55000 美元。最后，Dimensional Fund Advisors LP 在第三季度将其在 PetMed Express 的持股增加了 5.4%。Dimensional Fund Advisors LP 目前拥有 481517 股该公司的股票，价值 1209000 美元，此前在上个季度购买了 24624 股。机构投资者和对冲基金持有该公司 73.33% 的股票。</p>
</div><h2>About PetMed Express</h2>
<div class="lb-trans"><h2>关于 PetMed Express</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.</p>
<div class="lb-trans"><p>PetMed Express, Inc 及其子公司在美国经营宠物药房。该公司销售处方和非处方宠物药物、健康产品及其他狗、猫和马的用品。它提供非处方药物和用品，如跳蚤和蜱虫控制产品、骨骼和关节护理产品、维生素、零食、营养补充品、卫生产品和家庭宠物用品；以及处方药物，包括心丝虫预防药、跳蚤和蜱虫预防药、关节炎、皮肤炎、甲状腺、糖尿病、止痛药、心脏/血压药物及其他特殊药物，以及仿制药替代品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than PetMed Express</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 PetMed Express 更好</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>高通的巨型反弹有个隐患——这只股票能否继续上涨？</li>
<li>如何投资蓝筹股</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PETS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PetMed Express Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 PetMed Express 吗？</h2>
</div><p>Before you consider PetMed Express, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PetMed Express 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 PetMed Express 并不在名单上。</p>
</div><p>While PetMed Express currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PetMed Express 目前在分析师中被评为 “卖出”，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PetMed Express (PETS) 预计将在周三公布财报